CF PHARMTECH (02652) shares experienced a significant uptick, rising more than 5% in trading. As of the latest report, the stock was up 4.84%, trading at HK$16.89, with a transaction volume of HK$65.3977 million.
On the news front, the company announced that it has successfully completed the placement of 21,747,700 new H-shares on August 6, 2026. The placement price was set at HK$13.82 per H-share, generating net proceeds of approximately HK$295 million. According to the company's prior disclosure, about 70% of the net proceeds will be allocated to the clinical and preclinical development of the group's innovative drug candidates. An additional 15% is earmarked for global development costs, including CMC research, clinical studies, device development, and regulatory filing expenses for the group's complex inhaled formulation products, such as CF048, CF059/CF060, CF066 EDS, CF067, CF068, and CF011/CF088.
It is reported that CF PHARMTECH has established a comprehensive inhaled formulation platform covering research, production, and global registration. The company possesses R&D and manufacturing capabilities across multiple technology pathways, including nebulizers, metered-dose inhalers, dry powder inhalers, nasal sprays, soft mist inhalers, small interfering RNA, and liposomal inhaled delivery systems. This forms a complete progression from multi-dosage form platform construction to original innovation. The clinical trial application for the company's self-developed innovative drug ICF001 has been formally accepted by the National Medical Products Administration. Currently, no specific drugs are approved for pulmonary hypertension associated with interstitial lung disease (PH-ILD) in China. ICF001 is expected to become the first inhaled drug approved for treating PH-ILD in the country, potentially filling this critical clinical gap.
Comments